Emerging Therapeutic Strategies in Prostate Cancer: Targeted Approaches Using PARP Inhibition, PSMA-Directed Therapy, and Androgen Receptor Blockade with Olaparib, Lutetium (&lt;sup&gt;177&lt;/sup&gt;Lu)Vipivotide Tetraxetan, and Abiraterone. This evidence concerns the gene FOLH1 and prostate carcinoma.